American Industrial Partners to Acquire Avanos Medical in $1.272B Take Private Deal

Why It Matters

The deal provides Avanos investors a sizable cash premium while giving AIP a platform to scale and modernize a cash‑generating medical‑device business, reinforcing consolidation trends in the sector.

Key Takeaways

• AIP to acquire Avanos for $1.272 billion cash
• Shareholders receive $25 per share, 72% premium
• Deal will take Avanos private, delist from NYSE
• Closing expected H2 2026, expanding AIP’s healthcare holdings

Pulse Analysis

American Industrial Partners (AIP), a private‑equity firm with a growing focus on healthcare, announced a definitive agreement to acquire Avanos Medical in an all‑cash transaction valued at roughly $1.272 billion. The deal reflects AIP’s strategy of consolidating niche medical‑device businesses that generate steady cash flow and have defensible product portfolios. By taking Avanos private, AIP can implement operational improvements without the scrutiny of public markets, while leveraging its existing platform of health‑care assets to drive cross‑selling opportunities. The premium paid underscores the firm’s confidence in the long‑term growth of minimally invasive therapy solutions.

Avanos Medical, headquartered in Alpharetta, Georgia, designs and manufactures devices for respiratory, pain‑management and vascular access applications, serving hospitals and home‑care settings worldwide. Its flagship products, such as the ClearFlow tracheostomy tube and the Opioid‑Free Anesthesia platform, have captured significant market share and benefit from recurring revenue streams through consumable sales. The $25 per share offer represents a 72 percent premium to the April 13 closing price, indicating that AIP values Avanos’s recurring cash generation and pipeline potential. The acquisition also removes the company from NYSE reporting requirements, allowing more flexible capital allocation.

The transaction, slated to close in the second half of 2026, will expand AIP’s footprint in the medical‑device sector and could trigger further consolidation among specialized manufacturers seeking scale. For Avanos shareholders, the cash premium provides an immediate return, while employees may see increased investment in R&D under private ownership. Industry observers will watch how AIP integrates Avanos with its other health‑care holdings to achieve cost synergies and accelerate product innovation. In a market where private equity is increasingly active, the deal highlights the premium placed on stable, cash‑rich medical‑technology businesses.

Deal Summary

American Industrial Partners' affiliates have signed a definitive agreement to acquire Avanos Medical in an all‑cash transaction valued at approximately $1.272 billion. Avanos shareholders will receive $25 per share, a 72.1% premium, and the company will be taken private and delisted from the NYSE, with closing expected in the second half of 2026.